Willie Yu received his MSc in Bioinformatics from Boston University and his PhD in Bioinformatics from National University of Singapore (NUS). His PhD thesis focused on deciphering acquired mutations associated with the development of rare cancers such as liver fluke-associated cholangiocarcinoma, well-differentiated papillary mesothelioma and parathyroid carcinoma using whole-exome analysis. Dr. Yu’s contribution was instrumental in the development of genome-wide cancer signatures associated with exposure to aristocholic acid, a potent carcinogen present in certain Chinese herbal medicines, and exposure to aflatoxin, an IARC (International Agency for Research on Cancer) Group 1 carcinogen known to cause liver cancer. Dr. Yu has extensive experience in Big Data analysis of cancer genomes and exomes, including application of Machine Learning techniques, with 20+ peer-reviewed articles in the area of cancer genome and exome analysis. In addition, Dr. Yu has a cross-discipline interest in quantitative trading strategies and has over 10 publications in the areas of asset management and investment strategies. Currently, Dr. Yu is a research fellow at the Centre for Computational Biology at Duke-NUS Medical School (Singapore) with a concentration in software creation for large scale parallel integrative analysis of cancer genomes, exomes, transcriptomes and gene expression microarrays.